Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator (PoNS), a medical device in Canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. Its PoNS device treats neurostimulation of cranial nerves via the tongue to restore lost function. The company is headquartered in Newtown, Pennsylvania.
Research context
Helius Medical Technologies, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Helius Medical Technologies, Inc is currently in a long term downtrend where the price is trading 97.7% below its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.9.
Helius Medical Technologies, Inc's total revenue sank by 12.7% to $131K since the same quarter in the previous year.
Its net income has increased by 37.8% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 51.0% to $-3M since the same quarter in the previous year.
Based on the above factors, Helius Medical Technologies, Inc gets an overall score of 3/5.